-
Five-year agreement supports access to cost-effective, integrated
renal care through awareness building, education and research,
particularly in low- and middle-income countries
-
Efforts include focus on unmet need to diagnose and treat chronic
kidney disease earlier to help slow disease progression
DEERFIELD, Ill. & BRUSSELS--(BUSINESS WIRE)--
Baxter
International Inc. (NYSE:BAX), a global innovator in renal (kidney)
care, and the International Society of Nephrology (ISN) announced a
partnership to advance chronic kidney disease (CKD) awareness and help
improve access to therapy, particularly in low- and middle-income
countries (LMIC) – commonly referenced as emerging markets – where the
disease prevalence is growing the fastest. The collaboration will
support greater disease and therapy research and education, as well as
work to help establish better care models that support high standards of
care at a lower cost in LMIC.
“ISN and Baxter’s collaboration aims to address the urgent and growing
challenge kidney disease is causing healthcare systems in providing
quality care to patients globally,” said David Harris, M.D., ISN
President, University of Sydney, Australia. “Our organization is
dedicated to connecting communities to collaborate on supporting greater
access to care models that focus on how to improve prevention, diagnosis
and treatment of kidney disease.”
Chronic kidney disease affects 10 percent of the global population.
Additionally, it is estimated there are as many as four million people
with end-stage renal disease (ESRD) globally, which is the last stage of
the disease progression and requires dialysis or a kidney transplant to
stay alive. It’s further estimated that millions more go undiagnosed and
untreated globally.
“It is Baxter’s goal to make renal care available to people in need,
while driving better outcomes through new standards,” said Laura
Angelini, general manager, Baxter’s Renal Care business. “Our
partnership with ISN moves us closer to this goal by combining Baxter’s
clinical and innovation expertise with ISN’s educational and research
expertise in a truly transformative approach to increasing access to
care worldwide.”
About Baxter
Baxter provides a broad portfolio of essential healthcare products
across its portfolio, including acute and chronic dialysis therapies;
sterile IV solutions; infusion systems and devices; parenteral nutrition
therapies; inhaled anesthetics; generic injectable pharmaceuticals; and
surgical hemostat and sealant products. The company’s global footprint
and the critical nature of its products and services play a key role in
expanding access to healthcare in emerging and developed countries.
Baxter’s employees worldwide are building upon the company’s rich
heritage of medical breakthroughs to advance the next generation of
healthcare innovations that enable patient care.
About ISN
The International Society of Nephrology (ISN) is a philanthropic
organization dedicated to advancing worldwide kidney health. We do this
for all our stakeholders by:
-
BRIDGING THE GAPS of available care through advocacy and
collaborations with our global partners
-
BUILDING CAPACITY in healthcare professionals via granting programs,
education and research
-
CONNECTING OUR COMMUNITY to develop a stronger understanding of the
management of kidney disease.
With over 10,000 professional members from over 160 countries, the ISN
represents a wide international network and an efficient platform for
timely scientific exchange, debate and communication between healthcare
professionals involved in preventing and treating kidney disease. By
collaborating with more than 100 national
and regional societies, we reach out to an additional 30,000 health
professionals globally.
Our overarching purpose is to tackle the global burden of acute kidney
injury (AKI),
chronic kidney disease (CKD)
and end-stage kidney disease (ESKD),
improving patient care through an interconnected advocacy, education and research
strategy.
www.theisn.org
Baxter is a registered trademark of Baxter International Inc.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20180502005367/en/
ISN Media Contact
Luca Segantini, Executive Director, +32
28080420
lsegantini@theisn.org
or
Baxter
Media Contact
Jill Carey-Hargrave, (224) 948-5353
media@baxter.com
or
Baxter
Investor Contact
Clare Trachtman, (224) 948-3085
Source: Baxter International Inc.